5 Best Price Comparison for February 2026
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
In the current market environment, digital services and online platforms present compelling value opportunities, particularly amid fluctuating consumer spending and tech sector rotations. ValueSense analysis highlights stocks trading significantly below their intrinsic value, selected using proprietary tools that blend ROIC, free cash flow margins, revenue growth, and quality ratings. These picks were screened for strong fundamentals like high gross margins and low debt-to-equity ratios, focusing on companies in the internet services and healthcare tech spaces. Criteria emphasize undervaluation (intrinsic value far exceeding implied current pricing), positive cash generation, and sector diversification within digital economies. This methodology, powered by ValueSense's institutional-grade screeners, identifies potential mispricings for educational analysis.
Featured Stock Analysis
Stock #1: Ziff Davis, Inc. (ZD)
| Metric | Value |
|---|---|
| Market Cap | $1,560.2M |
| Quality Rating | 5.9 |
| Intrinsic Value | $171.5 |
| 1Y Return | -29.2% |
| Revenue | $1,457.4M |
| Free Cash Flow | $261.2M |
| Revenue Growth | 5.7% |
| FCF margin | 17.9% |
| Gross margin | 61.2% |
| ROIC | 6.1% |
| Total Debt to Equity | 48.1% |
Investment Thesis
Ziff Davis, Inc. (ZD) stands out in ValueSense analysis with a Quality rating of 5.9 and an intrinsic value of $171.5, suggesting substantial undervaluation relative to its market position. The company reports a Market Cap of $1,560.2M, Revenue of $1,457.4M, and robust Free Cash Flow of $261.2M, underpinned by a healthy FCF margin of 17.9% and Gross margin of 61.2%. Despite a 1Y Return of -29.2%, modest Revenue growth of 5.7% and ROIC of 6.1% indicate operational stability in digital media and services. Total Debt to Equity at 48.1% remains manageable, positioning ZD for potential recovery as market sentiment shifts toward value-oriented tech plays. This analysis frames ZD as an educational case study in cash-generative businesses trading at a discount.
Key Catalysts
- Strong Free Cash Flow generation at $261.2M supports reinvestment and shareholder returns.
- High Gross margin of 61.2% reflects pricing power in digital content and services.
- Steady Revenue growth of 5.7% amid sector volatility signals resilient demand.
Risk Factors
- Negative 1Y Return of -29.2% highlights short-term market pressures.
- Elevated Total Debt to Equity of 48.1% could strain finances in rising rate environments.
- Modest ROIC of 6.1% may limit aggressive expansion without efficiency gains.
Stock #2: EverQuote, Inc. (EVER)
| Metric | Value |
|---|---|
| Market Cap | $808.2M |
| Quality Rating | 6.9 |
| Intrinsic Value | $86.2 |
| 1Y Return | 9.1% |
| Revenue | $644.7M |
| Free Cash Flow | $87.5M |
| Revenue Growth | 57.8% |
| FCF margin | 13.6% |
| Gross margin | 96.8% |
| ROIC | 301.4% |
| Total Debt to Equity | 0.5% |
Investment Thesis
EverQuote, Inc. (EVER) earns a strong Quality rating of 6.9 in ValueSense data, with an intrinsic value of $86.2 pointing to deep undervaluation. Featuring a Market Cap of $808.2M, Revenue of $644.7M, and Free Cash Flow of $87.5M, the company boasts explosive Revenue growth of 57.8% and an exceptional ROIC of 301.4%. FCF margin stands at 13.6%, complemented by a near-perfect Gross margin of 96.8% and minimal Total Debt to Equity of 0.5%. Positive 1Y Return of 9.1% underscores momentum in insurance quoting platforms. This profile offers educational insights into high-growth, low-debt digital marketplaces with scalable economics.
Key Catalysts
- Breakout Revenue growth of 57.8% driven by expanding online insurance demand.
- Outstanding ROIC of 301.4% demonstrates superior capital efficiency.
- Ultra-low Total Debt to Equity of 0.5% enables flexible growth strategies.
Risk Factors
- Dependence on cyclical insurance sector could amplify volatility.
- High Gross margin of 96.8% vulnerable to competitive pricing pressures.
- Scaling Free Cash Flow from $87.5M needs sustained growth to match revenue pace.
Stock #3: GoodRx Holdings, Inc. (GDRX)
| Metric | Value |
|---|---|
| Market Cap | $791.1M |
| Quality Rating | 6.1 |
| Intrinsic Value | $12.3 |
| 1Y Return | -54.1% |
| Revenue | $800.7M |
| Free Cash Flow | $86.6M |
| Revenue Growth | 1.3% |
| FCF margin | 10.8% |
| Gross margin | 91.0% |
| ROIC | 10.8% |
| Total Debt to Equity | 10.2% |
Investment Thesis
GoodRx Holdings, Inc. (GDRX) shows a Quality rating of 6.1, with intrinsic value at $12.3 amid a Market Cap of $791.1M. Key metrics include Revenue of $800.7M, Free Cash Flow of $86.6M (FCF margin 10.8%), and Gross margin of 91.0%. ROIC of 10.8% and low Total Debt to Equity of 10.2% support stability, despite 1Y Return of -54.1% and slow Revenue growth of 1.3%. As a healthcare tech disruptor in prescription savings, GDRX exemplifies ValueSense's focus on high-margin, asset-light models trading below intrinsic worth for analytical study.
Key Catalysts
- Impressive Gross margin of 91.0% from platform efficiencies in pharma services.
- Solid Free Cash Flow of $86.6M funds ongoing platform enhancements.
- Low Total Debt to Equity of 10.2% provides balance sheet strength.
Risk Factors
- Sharp 1Y Return decline of -54.1% reflects healthcare reimbursement headwinds.
- Anemic Revenue growth of 1.3% risks market share erosion.
- Regulatory changes in drug pricing could impact core economics.
Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.
Want to see what we'll uncover next - before everyone else does?
Find Hidden Gems First!
Stock #4: QuinStreet, Inc. (QNST)
| Metric | Value |
|---|---|
| Market Cap | $760.0M |
| Quality Rating | 6.1 |
| Intrinsic Value | $9.2 |
| 1Y Return | -45.6% |
| Revenue | $1,100.3M |
| Free Cash Flow | $113.1M |
| Revenue Growth | 43.1% |
| FCF margin | 10.3% |
| Gross margin | 9.9% |
| ROIC | 4.5% |
| Total Debt to Equity | 2.8% |
Investment Thesis
QuinStreet, Inc. (QNST) receives a Quality rating of 6.1, with intrinsic value of $9.2 against a Market Cap of $760.0M. It generates Revenue of $1,100.3M and Free Cash Flow of $113.1M (FCF margin 10.3%), fueled by robust Revenue growth of 43.1%. However, Gross margin is low at 9.9%, ROIC at 4.5%, and 1Y Return at -45.6%, with Total Debt to Equity of 2.8%. This performance marketing firm highlights ValueSense's screening for growth amid thin margins, offering lessons in performance-driven digital advertising.
Key Catalysts
- Strong Revenue growth of 43.1% from expanding client performance networks.
- Healthy Free Cash Flow of $113.1M supports operational scaling.
- Low Total Debt to Equity of 2.8% minimizes financial leverage risks.
Risk Factors
- Weak Gross margin of 9.9% exposes to cost inflation in ad tech.
- Low ROIC of 4.5% suggests capital allocation challenges.
- 1Y Return drop of -45.6% tied to advertising market slowdowns.
Stock #5: MoneyHero Limited Class A Ordinary Shares (MNY)
| Metric | Value |
|---|---|
| Market Cap | $42.7M |
| Quality Rating | 4.6 |
| Intrinsic Value | $13.0 |
| 1Y Return | 13.0% |
| Revenue | $69.2M |
| Free Cash Flow | $0.0 |
| Revenue Growth | (22.5%) |
| FCF margin | 0.0% |
| Gross margin | 43.0% |
| ROIC | (361.5%) |
| Total Debt to Equity | 3.0% |
Investment Thesis
MoneyHero Limited Class A Ordinary Shares (MNY) has a Quality rating of 4.6, intrinsic value of $13.0, and small Market Cap of $42.7M. Metrics show Revenue of $69.2M, zero Free Cash Flow (FCF margin 0.0%), Revenue growth of 22.5%, Gross margin of 43.0%, negative ROIC of 361.5%, and Total Debt to Equity of 3.0%. Positive 1Y Return of 13.0% contrasts operational struggles in financial comparison platforms. ValueSense data frames MNY as a high-risk, small-cap case for turnaround potential in fintech.
Key Catalysts
- Positive 1Y Return of 13.0% amid broader sector recovery.
- Manageable Total Debt to Equity of 3.0% for a micro-cap.
- Gross margin of 43.0% offers baseline profitability runway.
Risk Factors
- Negative Revenue growth of 22.5% signals contracting operations.
- Zero Free Cash Flow and negative ROIC of 361.5% indicate cash burn.
- Tiny Market Cap amplifies volatility and liquidity concerns.
Portfolio Diversification Insights
These five stocks cluster in the digital services sector, primarily internet content, insurance quoting, healthcare tech, performance marketing, and fintech comparisons, providing intra-sector diversification. EVER and QNST offer high-growth exposure (57.8% and 43.1% revenue growth), balancing ZD and GDRX's stability (high FCF margins of 17.9% and 10.8%). MNY adds small-cap spice with higher risk. Allocation suggestion: 25% EVER (top ROIC), 20% each ZD/GDRX/QNST, 15% MNY. Low average debt-to-equity (~13%) enhances resilience, while varied margins (9.9%-96.8%) hedge economic cycles. Cross-analysis shows EVER's strength complementing others' cash flows for a balanced watchlist.
Market Timing & Entry Strategies
Consider entry during sector dips, such as post-earnings volatility or broader tech pullbacks, when intrinsic value gaps widen. Monitor ROIC trends and FCF for confirmation—e.g., EVER's 301.4% ROIC signals strength above 50-day averages. Use dollar-cost averaging for positions, starting small (5-10% portfolio) on 10-20% undervaluation pullbacks. Track revenue growth inflection points, like QNST's 43.1%, via ValueSense screeners. Educational strategy: Pair with backtested filters for ROIC >10% and debt/equity <20%.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- Nelson Peltz - Trian Fund Management Portfolio Q3'2025: Top Holdings & Recent Changes
- Principles for Dealing with the Changing World Order by Ray Dalio
- The Ascent of Money by Niall Ferguson
- Principles for Navigating Big Debt Crises by Ray Dalio
- Influence: The Psychology of Persuasion by Robert B. Cialdini Ph.D.
FAQ Section
How were these stocks selected?
These stocks were chosen via ValueSense's proprietary screening for high intrinsic value upside, quality ratings above 4.5, strong FCF margins, and digital sector focus, emphasizing ROIC and low debt.
What's the best stock from this list?
EVER stands out with the highest Quality rating 6.9, explosive 57.8% revenue growth, and 301.4% ROIC, making it a top analytical pick for growth-value balance.
Should I buy all these stocks or diversify?
Diversification across these digital services plays reduces sector risk; allocate based on risk tolerance, favoring EVER and ZD for stability while limiting MNY exposure.
What are the biggest risks with these picks?
Key risks include revenue volatility (e.g., MNY's -22.5%), negative returns (GDRX -54.1%), and thin margins (QNST 9.9%), amplified by market cycles.
When is the best time to invest in these stocks?
Optimal timing aligns with undervaluation expansions, positive FCF inflection, or sector recoveries—use ValueSense tools to monitor intrinsic value gaps dynamically.